Overview

This trial is active, not recruiting.

Condition amphetamine-related disorders
Treatment reserpine
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date January 2004
End date November 2004
Trial size 30 participants
Trial identifier NCT00267657, NIDA-CPU-0006-1

Summary

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

Measure
Craving
time frame:
Cardiovascular
time frame:
Subjective symptoms/Mood Effects
time frame:
CNS norepinephrine turnover
time frame:

Eligibility Criteria

Male or female participants from 21 years up to 45 years old.

Inclusion Criteria: - Please contact site for more details Exclusion Criteria: - Please contact site for more details

Additional Information

Official title Assessment of Interactions Between IV Methamphetamine and Reserpine
Principal investigator Reese Jones, M.D.
Description In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Trial information was received from ClinicalTrials.gov and was last updated in October 2007.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).